Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts…
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts…
Choosing where to plant your biotech company’s roots is a fundamental question driven by access…
You’ve got the idea. You’ve got the science. You’ve got the team. Now all you…
Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are…
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
Biotechs always start with great scientific ideas, but if you can’t protect them, you can’t…
Talented executives are always in demand in the biotech industry. Leaders who stand out in…
With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the…
Biotech investment rounds tend to draw big headlines, but experienced players know the real work…
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month…
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled…